Back to Search

A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

Recruiting Observational Study
Multiple Sclerosis
Ready to participate?

Review the details below, then apply to join this clinical trial.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosis of MS * RMS and PPMS participants diagnosed according to the McDonald criteria of 2017 or revised McDonald criteria 2024 * First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for…
Contacts

Reference Study ID Number: ML45551 https://forpatients.roche.com/ No attachments to email below

888-662-6728 (U.S. Only)

global-roche-genentech-trials@gene.com

CONTACT

Fastest response: use the inquiry form https://www.gene.com/contact-us/submit-medical-inquiry

CONTACT

NCT ID: NCT06780150 Source: ClinicalTrials.gov